Last reviewed · How we verify
Pharmacologic Stress Agent
Pharmacologic Stress Agent is a Small molecule drug developed by Cedars-Sinai Medical Center. It is currently in Phase 2 development. Also known as: regadenoson, adenosine, stress agent.
-
Baseline phase 2 → approval rate
+15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2031–2034 | — |
| EMA | EU | 2032–2035 | +0.7 yr |
| MHRA | GB | 2032–2035 | +0.7 yr |
| Health Canada | CA | 2032–2036 | +0.9 yr |
| TGA | AU | 2032–2036 | +1.2 yr |
| PMDA | JP | 2032–2036 | +1.5 yr |
| NMPA | CN | 2033–2037 | +2.3 yr |
| MFDS | KR | 2032–2036 | +1.4 yr |
| CDSCO | IN | 2032–2037 | +1.8 yr |
| ANVISA | BR | 2033–2037 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | Pharmacologic Stress Agent |
|---|---|
| Also known as | regadenoson, adenosine, stress agent |
| Sponsor | Cedars-Sinai Medical Center |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Effects of Relugolix vs Leuprolide on Cardiac Function in Patients With Prostate Cancer (PHASE2)
- Efficacy and Safety of Shatavari Root Extract in Women's Sexual Wellness (NA)
- Catheter Ablation Versus Anti-arrhythmic Drugs for Premature Ventricular Complexes (NA)
- REMIDEP-HTA Program for Hypertension Remission and Medication Deprescription (NA)
- Dalargin for Prevention of Organ Disfunction in High-Risk Abdominal Surgery (PHASE3)
- RAdiolabeled Perfusion to Identify Coronary Artery Disease Using WAter To Evaluate Responses of Myocardial FLOW (RAPID-WATER-FLOW) (PHASE3)
- The MATCH Investigation: CT Myocardial Perfusion and CT-FFR vs PET MPI (NA)
- Randomised Controlled Trial of an Antioxidant and Sunscreen Combination Cream for Reducing DNA Damage in Human Skin (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Pharmacologic Stress Agent CI brief — competitive landscape report
- Pharmacologic Stress Agent updates RSS · CI watch RSS
- Cedars-Sinai Medical Center portfolio CI
Frequently asked questions about Pharmacologic Stress Agent
What is Pharmacologic Stress Agent?
Who makes Pharmacologic Stress Agent?
Is Pharmacologic Stress Agent also known as anything else?
What development phase is Pharmacologic Stress Agent in?
Related
- Manufacturer: Cedars-Sinai Medical Center — full pipeline
- Also known as: regadenoson, adenosine, stress agent
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing